Abstract：ObjectiveTo investigate the clinical efficacy of Telmisartan combined with Sulodexide in the treatment of diabetic nephropathy.Methods64 patients with diabetic kidney disease at stageⅢtreated in our hospital from March 2015 to March 2017 were selected as subjects of this study.They were divided into control group and study group with random number table method,32 cases in each group.Two groups of patients were treated with conventional therapy,the patients of control group were given Telmisartan on the addition of conventional treatment,the patients of study group were given Telmisartan and Sulodexide on the basis of conventional treatment,all patients were treated for 8 weeks.The total effective rate of treatment,the serum creatinine(Scr),urea nitrogen(BUN),microprojection rate(UAER),high sensitivity C-reactive protein(hs-CRP)and tumor necrosis factor-α (TNF-α)before and after 8 weeks of treatmen were comapred between two groups.ResultsThe total effective rate in the study group(93.75%)was higher than that in the control group(68.75%),and the difference was statistically significant(P<0.05).There was no significant difference in the Scr,BUN and UAER between the two groups before treatment(P>0.05).After treatment,the UAER in both groups were lower than before treament,the UAER in the study group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in hs-CRP and TNF-α in the two groups(P>0.05).After treatment,the levels of hs-CRP and TNF-α in both groups were significantly lower than before treatment,and the levels of hs-CRP and TNF-α in the study group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).ConclusionThe efficacy of Telmisartan combined with Sulodexide in the treatment of diabetic kidney disease is significantly better than that of telmisartan alone,and it is recommended to be widely used clinically.
京公网安备 11010502046607号